Indication

As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.

Medicine details

Medicine name:
olaparib (Lynparza)
SMC ID:
SMC2366
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
13 September 2021
SMC meeting date:
03 August 2021
Patient group submission deadline:
31 May 2021